Table 1 Patient baseline characteristics of the two study cohorts.
Full cohort | Subcohort | |||||
|---|---|---|---|---|---|---|
Females | Males | P-value (effect size) | Females | Males | P-value (effect size) | |
No. of patients | 173 | 614 | 43 | 148 | ||
Age, years | 63.0 (53.2, 70.8) | 62.3 (54.3, 69.7) | 0.443 | 64.5 (56.0, 72.1) | 62.1 (54.3, 69.7) | 0.260 |
BMI | 27.3 (24.2, 30.5) | 27.1 (24.9, 29.9) | 0.926 | 27.7 (24.4, 29.5) | 27.5 (25.0, 30.0) | 0.669 |
Heart rate, bpm | 73 (65, 86) | 71 (62, 84) | 0.028 (small) | 76 (62, 85) | 71.5 (62.5, 83.3) | 0.520 |
SBP, mmHg | 144.5 (128.8, 160.0) | 136.0 (120.0 155.0) | 0.005 (small) | 142 (122, 150.5) | 135 (115, 154) | 0.480 |
Serum creatinine, µmol/L | 68.0 (60.0, 82.0) | 85.0 (73.0, 98.5) | < 0.001 (medium) | 68.0 (61.5, 76.5) | 86.0 (75.0, 100.5) | < 0.001 (medium) |
Cardiovascular risk factors | ||||||
Diabetes mellitus | 46 (26.6) | 130 (21.2) | 0.098 | 7 (16.3) | 26 (17.6) | 0.844 |
Hypertension | 106 (61.3) | 329 (53.6) | 0.036 (small) | 26 (60.5) | 75 (50.7) | 0.258 |
Hypercholesterolemia | 84 (48.6) | 302 (49.2) | 0.924 | 25 (58.1) | 67 (45.3) | 0.137 |
Current smoker | 73 (42.2) | 244 (39.7) | 0.012 (small) | 19 (44.2) | 61 (41.2) | 0.207 |
Positive family history | 87 (50.3) | 311 (50.7) | 0.902 | 21 (53.8) | 66 (52.8) | 0.909 |
Cardiovascular history | ||||||
Angina | 71 (41.0) | 211 (34.4) | 0.069 | 18 (41.9) | 53 (35.8) | 0.470 |
CAD | 46 (26.6) | 215 (35.0) | 0.054 | 8 (18.6) | 45 (30.4) | 0.128 |
MI | 30 (17.3) | 178 (29.0) | 0.003 (small) | 7 (16.3) | 43 (29.1) | 0.093 |
PCI | 35 (20.2) | 168 (27.4) | 0.076 | 6 (14.0) | 38 (25.9) | 0.104 |
CABG | 10 (5.8) | 62 (10.1) | 0.100 | 1 (2.3) | 13 (8.8) | 0.198 |
CHF | 2 (1.2) | 14 (2.3) | 0.543 | 0 (0.0) | 4 (2.7) | 0.576 |
Valvular heart disease | 2 (1.2) | 12 (2.0) | 0.745 | 1 (2.3) | 2 (1.4) | 0.537 |
Stroke | 17 (9.8) | 49 (8.0) | 0.434 | 7 (16.3) | 12 (8.1) | 0.146 |
PVD | 13 (7.5) | 50 (8.1) | 1.000 | 2 (4.7) | 10 (6.8) | 0.999 |
Presentation on admission | ||||||
Diagnosis | 0.253 | 0.890 | ||||
STEMI | 84 (48.6) | 327 (53.3) | 20 (46.5) | 73 (49.3) | ||
NSTEMI | 61 (35.2) | 224 (36.5) | 18 (41.9) | 56 (37.8) | ||
Unstable angina pectoris | 23 (13.3) | 57 (9.3) | 5 (11.6) | 19 (12.8) | ||
Culprit artery | ||||||
RCA | 50 (28.9) | 213 (34.7) | 0.175 | 12 (27.9) | 47 (31.8) | 0.231 |
LM | 5 (2.9) | 15 (2.4) | 0.784 | 2 (4.7) | 4 (2.7) | 0.618 |
LAD | 57 (32.9) | 194 (31.6) | 0.680 | 16 (37.2) | 52 (35.1) | 0.063 |
LCX | 26 (15.0) | 103 (16.8) | 0.616 | 7 (16.3) | 20 (13.5) | 0.210 |
Coronary angiography performed | 159 (91.9) | 587 (95.6) | 0.053 | 40 (93.0) | 140 (94.6) | 0.713 |
PCI performed | 123 (71.1) | 512 (83.4) | 0.001 (small) | 30 (75.0) | 117 (84.2) | 0.182 |
Maximum CK-MB during admission | 76.0 (38.0, 157.0) | 71.0 (29.0, 192.5) | 0.854 | 76.0 (46.0, 133.0) | 83.0 (30.5, 150.5) | 0.955 |
GRACE risk score | 93 (77, 115) | 95 (78, 116) | 0.340 | 109 (91, 127) | 109 (88, 129) | 0.845 |
Discharge medication | ||||||
Aspirin | 158 (91.3) | 591 (96.3) | 0.214 | 40 (95.2) | 143 (96.6) | 0.651 |
P2Y12 platelet inhibitor | 159 (91.9) | 579 (94.3) | 0.560 | 41 (95.3) | 136 (91.9) | 0.739 |
Beta blocker | 153 (88.4) | 546 (88.9) | 0.361 | 38 (90.5) | 129 (87.2) | 0.338 |
ACEi | 92 (53.2) | 434 (70.7) | < 0.001 (small) | 27 (64.3) | 111 (75.0) | 0.169 |
ARB | 31 (17.9) | 87 (14.2) | 0.180 | 5 (11.9) | 17 (11.5) | 0.999 |
Statin | 161 (93.1) | 587 (95.6) | 1.000 | 41 (97.6) | 142 (95.9) | 0.999 |
Vitamin K antagonist | 11 (6.4) | 38 (6.2) | 0.860 | 3 (7.0) | 11 (7.4) | 0.999 |
Insulin | 17 (9.8) | 47 (7.7) | 0.342 | 4 (9.3) | 12 (8.1) | 0.760 |
